Well-ionization chamber response relative to NIST air-kerma strength standard for prostate brachytherapy seeds
- PMID: 11099196
- DOI: 10.1118/1.1290715
Well-ionization chamber response relative to NIST air-kerma strength standard for prostate brachytherapy seeds
Abstract
The response of well-ionization chambers to the emissions of 103Pd and 125I radioactive seed sources used in prostate cancer brachytherapy has been measured. Calibration factors relating chamber response (current or dial setting) to measured air-kerma strength have been determined for seeds from nine manufacturers, each with different designs. Variations in well-ionization chamber response relative to measured air-kerma strength have been observed because of differences in the emitted energy spectrum due to both the radionuclide support material (125I seeds) and the mass ratio of 103Pd to 102Pd (103Pd seeds). Obtaining accurate results from quality assurance measurements using well-ionization chambers at a therapy clinic requires knowledge of such differences in chamber response as a function of seed design.
Similar articles
-
Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code.Med Phys. 2003 Apr;30(4):701-11. doi: 10.1118/1.1562942. Med Phys. 2003. PMID: 12722822
-
Monte Carlo aided design of an improved well-type ionization chamber for low energy brachytherapy sources.Med Phys. 2007 Apr;34(4):1274-85. doi: 10.1118/1.2712416. Med Phys. 2007. PMID: 17500459
-
103Pd loaded cartridge air kerma strength verification.Med Dosim. 1999 Spring;24(1):73-5. doi: 10.1016/s0958-3947(98)00056-9. Med Dosim. 1999. PMID: 10100171
-
Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.Med Phys. 2005 May;32(5):1424-39. doi: 10.1118/1.1884925. Med Phys. 2005. PMID: 15984693 Review.
-
Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources. A report of ICRP Publication 98.Ann ICRP. 2005;35(3):iii-vi, 3-50. doi: 10.1016/j.icrp.2005.07.001. Ann ICRP. 2005. PMID: 16330284 Review.
Cited by
-
Dosimetry and treatment planning of Occu-Prosta I-125 seeds for intraocular lesions.J Med Phys. 2008 Jan;33(1):14-8. doi: 10.4103/0971-6203.39419. J Med Phys. 2008. PMID: 20041047 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical